Livzon Seeks Mandate for 10% H-Share Buyback to Bolster Capital Flexibility

Livzon Pharmaceutical Group ( (HK:1513) ) has provided an announcement.

Livzon Pharmaceutical Group has convened its first 2026 class meeting of H shareholders to vote on a special resolution granting the board a general mandate to repurchase up to 10% of the company’s H shares. The proposed authorization would allow the board broad operational discretion over buyback terms, timing, regulatory filings, and subsequent share cancellation and capital reduction, signaling a potential move to optimize capital structure and support the H-share price, subject to shareholder and regulatory approvals.

If approved, the mandate will empower directors to set repurchase prices and volumes, manage required notifications, and handle procedural changes to the company’s articles reflecting a reduced share capital base. The resolution is conditional on parallel approval by A shareholders and relevant PRC and Hong Kong regulators, underscoring the company’s adherence to cross-border listing rules while potentially enhancing value for H-share investors through more flexible capital management.

The most recent analyst rating on (HK:1513) stock is a Sell with a HK$22.99 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.

More about Livzon Pharmaceutical Group

Livzon Pharmaceutical Group Inc. is a China-based pharmaceutical company listed in Hong Kong that operates in the healthcare and drug manufacturing sector. The group focuses on the development, production, and sale of pharmaceutical products, with its H shares traded on the Hong Kong Stock Exchange, serving both domestic and international investors.

Average Trading Volume: 914,703

Technical Sentiment Signal: Buy

Current Market Cap: HK$31.41B

See more data about 1513 stock on TipRanks’ Stock Analysis page.